The noisy failure of hydroxychloroquine to prove its effectiveness against Covid-19 has largely muted the announcement of much more real beneficial effects in another pathology: Sjögren’s syndrome. A study published in March in the Lancet Rheumatology shows the positive effects of a combined therapy of hydroxychloroquine and leflunomide (an anti-rheumatic drug) on this not so rare autoimmune disease which affects, in France, around 150,000 people and against which there is no curative treatment .
Identified at the beginning of the XXe century, this pathology affects the exocrine glands of the body, those which produce various fluids such as saliva, tears or mucus. The lymphocytes, wrongly stimulated to attack these organs, gradually colonize them, replacing the functional tissue with scar tissue. Result: dry eyes, mouth or vagina (90% of patients are women) which has a major impact on the quality of daily life, even